Cooley #1 for Life Sciences IPOs Year-to-Date

Palo Alto – June 24, 2020 – Cooley’s capital markets practice continues to lead in partnering with cutting-edge life sciences companies and their investment banks through the IPO process, despite the volatility caused by the COVID-19 pandemic. In 2020, Cooley is the #1 law firm for IPOs by life sciences companies year-to-date.

In June alone, Cooley has advised:

Repare Therapeutics on its $253 million IPO of 12,650,000 of its common shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Repare’s securities now trade on the Nasdaq Global Select Market under the symbol “RPTX.”

Legend Biotech on its $487.3 million IPO of 21,188,750 of its American Depository Shares (each representing two ordinary shares), which includes the full exercise of the underwriters’ option to purchase additional shares. This IPO demonstrates the collaboration between Cooley’s US and Asia offices. Legend’s securities now trade on the Nasdaq Global Select Market under the symbol “LEGN.”

The underwriters for Avidity Bioscience’s $298.1 million IPO of 16,560,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Avidity’s securities now trade on the Nasdaq Global Market under the symbol “RNA.”

Vaxcyte on its $287.5 million IPO of 17,968,750 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Vaxcyte’s securities now trade on the Nasdaq Global Select Market under the symbol “PCVX.”

The underwriters for Applied Molecular Transport’s $177.1 million IPO of 12,650,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. AMT’s securities now trade on the Nasdaq Global Select Market under the symbol “AMTI.”

The underwriters for Pliant Therapeutics’ $165.6 million IPO of 10,350,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Pliant’s securities now trade on the Nasdaq Global Select Market under the symbol “PLRX.”

The underwriters for Calliditas Therapeutics’ $90 million IPO of 9,230,770 of its common shares (including 4,153,385 American Depositary Shares, each representing two common shares). This IPO marks the first public offering by a Swedish listed company on Nasdaq US in five years. Calliditas’ securities now trade on the Nasdaq Global Select Market under the symbol “CALT.”

Additionally, in June, Cooley has advised on numerous notable securities transactions involving already-public issuers (either on the company- or bank-side), such as:

• Splunk’s $1.26 billion convertible senior notes offering
• Zendesk’s $1.15 billion convertible senior notes offering
• Guardant Health’s $1.1 billion follow-on offering
• Jazz Pharmaceuticals’ subsidiary’s $1 billion exchangeable senior notes offering
• Argenx’s $862.5 million follow-on offering
• Allogene Therapeutics’ $632.5 million follow-on offering
• Livongo Health’s $550 million convertible senior notes offering
• Arcus Biosciences’ $346.9 million follow-on offering
• Adaptimmune Therapeutics’ $244.8 million follow-on offering
• Glu Mobile’s $159.6 million follow-on offering
• Celldex Therapeuticss $141.7 million follow-on offering
• Evofem Biosciences’ $111 million follow-on offering
• Retrophin’s $100.8 million follow-on offering

Cooley has been the #1 law firm advising companies going public across all industries since 2014 and the #1 law firm for all venture-backed IPOs across all industries for 15+ years, according to IPO Vital Signs and PitchBook. Earlier this year, the firm earned a three-time Capital Markets Practice Group of the Year distinction by Law360 and was named one of the decade's top IPO legal advisers by Bloomberg Law. Cooley teams are working with more than 115 companies across the US, Europe and Asia – particularly in the life sciences and healthcare industries – on a host of COVID-19-related matters, including the development of vaccines, therapeutics, diagnostics and ventilators.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.